Showing results (101-110 of 2,810) with videos related to
Sort By:
Pageof 281
Expert Opinion on Drug Safety|September 23, 2016
Cardiovascular safety of therapies for type 2 diabetesPuneet Gupta, William B WhiteExpert Opinion on Drug Safety|September 24, 2016
The risk of cardiovascular side effects with anti-anginal drugsTalla A Rousan, Sunil T Mathew, Udho ThadaniExpert Opinion on Drug Safety|June 14, 2017
The safety of non-biological treatments in Ulcerative ColitisEdoardo Troncone, Giovanni MonteleoneExpert Opinion on Drug Safety|June 3, 2017
Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected womenKenneth K Mugwanya, Grace John-Stewart, Jared BaetenExpert Opinion on Drug Safety|June 3, 2017
A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseasesBram Verstockt, Barbara Deleenheer, Gert Van Assche, et al.Expert Opinion on Drug Safety|October 20, 2021
PARP inhibitors: clinical relevance and the role of multidisciplinary cancer teams on drug safetyMafalda Jesus, Manuel Morgado, Ana Paula DuarteExpert Opinion on Drug Safety|February 22, 2022
Flu vaccination in multiple sclerosis patients: a monocentric prospective vaccine-vigilance studyGiorgia Teresa Maniscalco, Cristina Scavone, Ornella Moreggia, et al.Expert Opinion on Drug Safety|October 11, 2021
Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infectionsMatteo Bassetti, Antonio Falletta, Giovanni Cenderello, et al.Expert Opinion on Drug Safety|October 20, 2021
A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertensionAndreas Katsanos, Ivano Riva, Banu Bozkurt, et al.Expert Opinion on Drug Safety|October 29, 2021
Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trialsKeizo Kanasaki, Shen Qu, Fumiko Yamamoto, et al.Pageof 281